Back to Cardiology
Cardiologyv2018Evidence-Based

Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Staging system for transthyretin amyloid cardiomyopathy using NT-proBNP and estimated glomerular filtration rate (eGFR) to stratify patients into prognostic categories for both wild-type and variant ATTR-CM

Clinical Input Parameters

ng/L
Range: 0 — 50000 ng/L
ml/min
Range: 5 — 150 ml/min
Clinical Assessment
Awaiting Parameters
gillmore stage
—stage
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Gillmore Staging System for Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within cardiology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Stage I: NT-proBNP ≤3000 ng/L AND eGFR ≥45 ml/min; Stage III: NT-proBNP >3000 ng/L AND eGFR <45 ml/min; Stage II: All other combinations

Clinical Pearls & Practice Notes

  • Developed by the UK National Amyloidosis Centre for both wild-type and variant ATTR-CM
  • Based on 869 patients with cardiac ATTR amyloidosis (553 wild-type, 316 variant)
  • Validated in a separate cohort of 318 patients
  • Uses readily available biomarkers (NT-proBNP and eGFR)
  • Stage I patients: 393 (45%) with median survival 69.2 months
  • Stage II patients: 334 (38%) with median survival 46.7 months
  • Stage III patients: 142 (16%) with median survival 24.1 months
  • Hazard ratios compared to Stage I: Stage II HR 2.05 (95% CI 1.54-2.72), Stage III HR 3.80 (95% CI 2.73-5.28)
  • Useful for clinical decision-making and trial design
  • Should be used in conjunction with comprehensive clinical evaluation
  • Regular monitoring of biomarkers recommended for disease progression assessment

Evidence & Literature Citations

  1. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. doi: 10.1093/eurheartj/ehx589.
  2. Fontana M, Corovic A, Scully P, Moon JC. Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging. 2019;12(11 Pt 2):2345-2356. doi: 10.1016/j.jcmg.2019.06.023.
  3. Grogan M, Scott CG, Kyle RA, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68(10):1014-1020. doi: 10.1016/j.jacc.2016.06.033.

Score Interpretation Ranges

Stage I1 – 1 pts

Best prognosis

Stage II2 – 2 pts

Intermediate prognosis

Stage III3 – 3 pts

Worst prognosis

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.